Rebecca Newberry, APRN
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $116,257 of the $155,610 with a category attached, or 74.7%. Lilly USA, LLC accounts for 69.6% of it on its own, with 31 other manufacturers making up the rest. Among family clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 658 payments — averaging $236.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$108K
- Novo Nordisk$42K
- AstraZeneca$757
- Bayer$707
- Mannkind Corporation$567
- Abbott$446
- plus $3K from 26 others
What the payments were for
- Consulting fees$16,91911%
- Speaking & faculty fees$116,25775%
- Travel & lodging$11,4727%
- Food & beverage$10,7087%
- Education$1360%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 389 | $108,359 |
| Novo Nordisk | 93 | $42,142 |
| AstraZeneca | 23 | $757 |
| Bayer | 19 | $707 |
| Mannkind Corporation | 22 | $567 |
| Abbott | 13 | $446 |
| Corcept Therapeutics | 13 | $390 |
| Dexcom, Inc. | 7 | $351 |
| Xeris Pharmaceuticals, Inc. | 19 | $327 |
| Sanofi-aventis U.S. LLC | 13 | $238 |
| AbbVie | 7 | $213 |
| Biohaven Pharmaceuticals, Inc. | 2 | $172 |
| Axsome Therapeutics, Inc. | 3 | $157 |
| Tandem Diabetes Care, Inc. | 1 | $108 |
| Boehringer Ingelheim | 6 | $90 |
| Ascensia Diabetes Care US Inc. | 5 | $90 |
| BETA Bionics, Inc. | 2 | $78 |
| Collegium Pharmaceutical, Inc. | 1 | $77 |
| Lifescan, Inc. | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Medtronic | 2 | $35 |
| Zealand Pharma US, Inc. | 1 | $30 |
| Amgen | 2 | $26 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| GRT US Holding, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$88,527
- RYBELSUS$15,138
- Ozempic$10,545
- TRULICITY$10,525
- Kerendia$468
- LOKELMA$250
- FreeStyle Libre$147
- FARXIGA$125
- QULIPTA$125
- Auvelity$118
- t:slim X2 Insulin Pump with Control-IQ$108
- AFREZZA$107
- FREESTYLE LIBRE 3$106
- NURTEC ODT$101
How this compares
$155,610 in reported general payments places this provider in the 95th percentile of 809 family providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 147 | $170,263 |
| OzempicSemaglutide | 43 | $59,002 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $33,559 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $33,063 |
| TrulicityDulaglutide | 21 | $26,456 |
| FarxigaDapagliflozin Propanediol | 28 | $26,097 |
| JardianceEmpagliflozin | 29 | $25,742 |
| InvokanaCanagliflozin | 11 | $17,960 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $16,443 |
| HumalogInsulin Lispro | 20 | $5,613 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $4,243 |
| Novolog FlexpenInsulin Aspart | 11 | $2,799 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,735 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $760 |
| Gabapentin | 33 | $671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $108,359 | $202,332188 claims |
| Novo NordiskOzempic | $42,142 | $59,00243 claims |
| AstraZenecaFarxiga | $757 | $26,09728 claims |
| Boehringer IngelheimJardiance | $90 | $25,74229 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $238 | $16,44316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Nebraska.
Other family in Omaha
- Stephanie SimonOmaha$157K
- Angela CraigOmaha$35K
- Laura FalconeOmaha$26K
- Brittany MatneyOmaha$14K
- Sara LegleiterOmaha$12K
- Jasper KaufmanOmaha$10K
- Stacy NiemiOmaha$10K
- Amy RuddickOmaha$10K
- Michaela AbbottOmaha$8K
- Margaret WallaceOmaha$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.